GHK-Cu for Skin, Hair, and Injections: Human Evidence

Q: What is GHK-Cu?

GHK-Cu is a complex of the three-amino-acid peptide glycyl-L-histidyl-L-lysine and copper. It occurs naturally in the body and is also used in cosmetic formulations.

Q: Does topical GHK-Cu improve skin?

Small studies and laboratory data support possible effects on skin repair and extracellular-matrix production. Human trials are small, and at least one randomized study found no objective advantage after laser resurfacing. The evidence is promising but limited.

Q: Does GHK-Cu regrow hair?

Laboratory and mouse studies support a possible mechanism, but strong controlled human evidence is missing. GHK-Cu should not be presented as a proven replacement for established hair-loss treatments.

Q: Is injectable GHK-Cu FDA-approved?

No. Injectable GHK-Cu is not an FDA-approved treatment. FDA states that compounded injectable GHK-Cu can present risks from aggregation, peptide-related impurities, and limited human safety information.

Q: Are copper peptide serum and injectable GHK-Cu supported by the same evidence?

No. Route matters. Topical studies cannot establish the safety or effectiveness of systemic injection. A claim must match the formulation and route that researchers tested.

Key takeaways

GHK-Cu is a natural copper-binding tripeptide. Laboratory studies support effects on skin cells and extracellular-matrix components.
Human topical evidence is small and mixed. It is stronger than the evidence for injected GHK-Cu, but it is not equal to large drug trials.
Hair-growth claims depend mainly on laboratory and animal evidence. There is no strong controlled human trial that shows injected GHK-Cu regrows hair.
FDA lists injectable GHK-Cu among bulk substances that can present significant safety risks in compounding because of limited human data and possible impurities or aggregates.

GHK-Cu is now used as one name for three different product categories: skin cosmetics, hair products, and injectable peptide programs. The evidence is not the same for all three.

Topical GHK-Cu has limited human evidence. Hair claims rely mainly on laboratory and animal studies. Injectable GHK-Cu has the largest safety and evidence gap.

This article separates those routes. It does not provide dose or injection instructions.

What is GHK-Cu?

GHK means glycyl-L-histidyl-L-lysine. It is a tripeptide, which means that it contains three amino acids. GHK can bind copper to form GHK-Cu.

Researchers study this complex because copper is important for enzymes involved in connective tissue and repair. The peptide can also affect cell signals. A mechanism is not a clinical result, but it explains why the ingredient became important in skin research.

Evidence for skin effects

The skin case starts with laboratory evidence.

A 1992 human fibroblast study found that GHK-Cu increased production of some glycosaminoglycans. These molecules help form the extracellular matrix around cells. The study used cultured cells. It did not test wrinkles or skin appearance in people.

A later cell study of copper compounds found low irritation potential for GHK-Cu in the tested keratinocyte model. This result supports more formulation work. It does not establish long-term safety for every cosmetic product.

Human evidence is small. A randomized study tested topical GHK-Cu products after carbon-dioxide laser resurfacing. Only 13 patients completed the study. Researchers found no significant objective difference in redness, wrinkles, or overall skin quality between groups. Patients who used GHK-Cu reported higher satisfaction.

This is a mixed result. It does not show that GHK-Cu has no skin effect. It shows that the objective clinical evidence is smaller and less certain than many marketing pages state.

Can GHK-Cu enter the skin?

Delivery is a central problem because GHK-Cu is hydrophilic. It does not move easily through the outer lipid-rich skin barrier.

An in-vitro human-skin study found measurable movement and retention of a copper tripeptide through isolated skin. Another microneedle study found that pretreatment with microneedles increased movement through laboratory skin models.

These studies test delivery. They do not prove a visible benefit in routine consumer use. Microneedling also changes the risk of irritation and contamination. A delivery method must not be treated as an outcome study.

Evidence for hair growth

GHK-Cu hair claims are plausible but not proved in strong human trials.

A 2023 formulation study tested a GHK-Cu microemulsion. The researchers reported effects on hair-related signals and hair growth in mice. Mouse hair growth is useful preclinical evidence. It does not predict the size or reliability of an effect in people with androgenetic alopecia, telogen effluvium, or another cause of hair loss.

The cause of hair loss matters. A product that affects skin repair does not automatically block dihydrotestosterone, correct iron deficiency, treat thyroid disease, or stop immune-mediated hair loss.

There is no strong controlled human trial that shows injected GHK-Cu regrows hair. Claims from photographs, social posts, and self-reports cannot control for minoxidil, finasteride, nutrition, time, or the natural hair cycle.

Topical and injectable GHK-Cu are different evidence questions

Topical research cannot prove systemic injection safety.

FDA lists GHK-Cu for injectable routes among bulk substances that can present significant safety risks in compounding. FDA gives two main reasons:

peptide aggregation and peptide-related impurities can cause an immune response;
human safety information is limited.

FDA's May 2026 compounding list separates non-injectable GHK-Cu from the injectable route. Non-injectable GHK-Cu remains under evaluation for possible 503A use. This status is not FDA approval and does not prove a cosmetic claim.

How strong is the evidence?

Claim	Evidence level	Practical conclusion
GHK-Cu changes fibroblast or matrix activity	Laboratory evidence	Biologically plausible
Topical GHK-Cu improves visible skin aging	Small and mixed human evidence	Possible, but not firmly established
Topical GHK-Cu regrows human hair	Mainly laboratory and animal evidence	Not proved
Injectable GHK-Cu improves skin, hair, or recovery	No strong controlled human evidence	Not established

The route, formulation, concentration, and outcome must match the cited study. A seller must not use a cell study to make an injection claim.

How to assess a product claim

Use five questions:

Did the study use people, animals, or cells?
Did researchers test a topical product or an injection?
Did the study measure appearance, hair count, wound closure, or only a laboratory marker?
Was there a control group?
Does the seller provide the complete formulation and a batch-specific quality report?

This method removes many exaggerated claims quickly.

Bottom line

GHK-Cu has a credible biological basis and useful early skin research. The topical evidence is more relevant than the injectable evidence, but the human trials are small. Hair-growth evidence remains mainly preclinical. Injectable use has limited human safety information and specific FDA compounding concerns.

GHK-Cu is a valid research subject. It is not a proved injectable treatment for skin aging, hair loss, or general recovery.

Sources

Educational information only. GHK-Cu is not FDA-approved as an injectable treatment for skin, hair, or recovery. This article does not recommend use or provide medical instructions.